Rocket Pharmaceuticals, Inc.
RCKT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001281895
In the last 90 days, Rocket Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 7 sales; 181 institutions reported holding it in 13F filings for Q2 2026, worth $340.9M in total; Maverick Capital is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 13, 2026, 1:18 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 26, 2024 | Feb 27, 2023 | Feb 24, 2022 |
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating expenses | $231.7M | $273.2M | $259.7M | $224.3M | $167.2M |
| Research and development | $142.0M | $171.2M | $186.3M | $165.6M | $125.5M |
| Selling, general and administrative | $86.5M | $102.0M | $73.3M | $58.8M | $41.8M |
| Operating income | -$231.7M | -$273.2M | -$259.7M | -$224.3M | -$167.2M |
| Interest expense | $1.89M | $1.89M | $1.88M | $1.86M | $2.98M |
| Income tax | $0 | – | $0 | – | – |
| Net income | -$223.1M | -$258.7M | -$245.6M | -$221.9M | -$169.1M |
| EPS, basic | $-2.01 | $-2.73 | $-2.92 | $-3.26 | $-2.67 |
| EPS, diluted | $-2.01 | $-2.73 | $-2.92 | $-3.26 | $-2.67 |
| Weighted shares, basic | 111.1M | 94.8M | 84.0M | 68.1M | 63.2M |
| Weighted shares, diluted | 111.1M | 94.8M | 84.0M | 68.1M | 63.2M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 26, 2024 | Feb 27, 2023 | Feb 24, 2022 |
| Cash and equivalents | $77.6M | $163.6M | $55.9M | $140.5M | $232.7M |
| Short-term investments | $111.4M | $208.7M | $317.3M | $215.9M | $156.0M |
| Total current assets | $192.7M | $378.2M | $378.2M | $364.1M | $392.1M |
| Property, plant and equipment | $28.2M | $36.8M | $39.2M | $29.0M | $22.3M |
| Goodwill | $39.2M | $39.2M | $39.2M | $39.2M | $30.8M |
| Intangible assets | $25.1M | $25.1M | $25.1M | $25.7M | – |
| Total assets | $330.4M | $527.7M | $566.3M | $551.8M | $497.0M |
| Total current liabilities | $30.2M | $40.7M | $48.5M | $39.2M | $22.2M |
| Total liabilities | $53.2M | $64.5M | $73.8M | $62.1M | $42.3M |
| Shareholders' equity | $277.2M | $463.2M | $492.6M | $489.7M | $454.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 26, 2024 | Feb 27, 2023 | Feb 24, 2022 |
| Operating cash flow | -$190.0M | -$209.7M | -$194.9M | -$178.1M | -$121.2M |
| Capital expenditures | $440.0K | $5.86M | $16.4M | $8.36M | $7.62M |
| Free cash flow | -$190.5M | -$215.6M | -$211.4M | -$186.5M | -$128.8M |
| Depreciation and amortization | $8.90M | $7.20M | $4.90M | – | – |
| Stock-based compensation | $37.1M | $43.9M | $39.4M | $31.0M | $29.2M |
| Share buybacks | – | – | – | – | $0 |
| Investing cash flow | $103.8M | $131.7M | -$98.1M | -$69.3M | $18.9M |
| Financing cash flow | $148.0K | $185.7M | $208.4M | $155.3M | $37.7M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 6, 2026 | 111.7M | +3.2% | SEC |
| Jul 31, 2026 | 109.8M | +1.7% | SEC |
| May 1, 2026 | 109.2M | +1.4% | SEC |
| Feb 20, 2026 | 108.6M | +1.8% | SEC |
| Oct 31, 2025 | 108.2M | +18.7% | SEC |
| Aug 1, 2025 | 107.9M | +18.6% | SEC |
| May 2, 2025 | 107.7M | +18.7% | SEC |
| Feb 21, 2025 | 106.6M | +17.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.